Orforglipron is an investigational oral GLP-1 medicine
Taste perception can vary significantly from person to person, limiting the generalizability of our results. While the weight loss results associated with semaglutide have been impressive, the drug is only suitable for certain people
When used for weight loss, they enhance your bodys own signals of fullness
Most GI side effects resolve within 7 to 14 days at the new dose level
3 The BMI threshold is 2.5 lower for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds, who are at higher risk of weight-related conditions at a lower BMI
The cherry on top is that neither of them can currently produce enough medicine to meet the demand